Related Experiment Video
Updated: Jun 21, 2026
09:03
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection
Pedram Hamrah1, Zdenka Haskova, Andrew W Taylor
1Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Transplantation
|July 23, 2009
Summary
Local therapy with alpha-Melanocyte stimulating hormone (alpha-MSH) significantly enhanced corneal allograft survival by reducing inflammation and immune rejection. This neuropeptide offers a promising, safer alternative for transplantation therapies.
Area of Science:
- Ophthalmology
- Immunology
- Transplantation Biology
Background:
- Corneal transplantation is the most common transplant procedure.
- Graft rejection and side effects of current therapies necessitate safer treatments.
- Alpha-Melanocyte stimulating hormone (alpha-MSH) is a neuropeptide with known anti-inflammatory properties.
Purpose of the Study:
- To investigate the efficacy of local alpha-MSH therapy in improving corneal allograft survival.
- To elucidate the mechanisms underlying alpha-MSH's potential effects on graft outcomes.
Main Methods:
- Orthotopic corneal transplantation in a mouse model.
- Subconjunctival injections of alpha-MSH or sham treatment administered twice weekly.
- Masked assessment of graft survival, inflammation, and opacification over 70 days.
- Evaluation of graft cellular infiltration, ocular cytokine gene expression, and delayed-type hypersensitivity.
Main Results:
- Alpha-MSH treatment significantly increased corneal graft survival rates (75% vs. 43% at 70 days).
- Reduced infiltration of inflammatory cells (mononuclear and polymorphonuclear) in grafts of alpha-MSH treated mice.
- Suppressed allospecific delayed-type hypersensitivity and expression of interferon-gamma and interleukin-2.
Conclusions:
- Local alpha-MSH therapy demonstrates significant potential in reducing corneal allograft rejection.
- Provides the first in vivo evidence for alpha-MSH's efficacy in preventing transplant rejection.
- Highlights alpha-MSH as a potential therapeutic agent for enhancing corneal transplant success.
Related Concept Videos
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...